Position in ZVRA
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$18,741,647
+$10,852,669 QoQ
Shares Held
1,306,949
+54.4% QoQ
Ownership
2.20%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#8
of 158 holders
Holding Since
Dec 2021
9 quarters on record
Voting authority
Sole 89%
Shared 0%
None 11%
Common Shares in ZVRA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026D. E. Shaw & Co., Inc. holds $5,139,216,221 across 217 Biotechnology names. ZVRA ranks #53 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
5,877,959 | $626,707,987 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,104,109 | $332,369,932 | |
| 3 | EXEL |
Exelixis, Inc.
|
5,551,747 | $302,070,554 | |
| 4 | BBIO |
BridgeBio Pharma, Inc.
|
3,633,007 | $270,586,360 | |
| 5 | TGTX |
Tg Therapeutics, Inc.
|
3,400,808 | $186,840,390 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
2,006,479 | $157,047,110 | |
| 7 | AXSM |
Axsome Therapeutics, Inc.
|
604,753 | $148,025,391 | |
| 8 | PTCT |
Ptc Therapeutics, Inc.
|
1,548,919 | $126,345,322 |
All Filings in ZVRA
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $18,741,647 | 1,306,949 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $7,888,978 | 846,457 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $7,739,163 | 863,746 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $6,902,642 | 725,830 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $1,667,847 | 189,313 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $205,001 | 27,370 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $209,125 | 25,075 | Shares | Defined | 2025-02-14 | |
| 2022-03-31 | $52,578 | 10,453 | Shares | Defined | 2022-05-16 | |
| 2021-12-31 | $207,376 | 23,809 | Shares | Defined | 2022-02-14 | |
| No filing history on record for this holder in this stock. | ||||||